SAGES Magazine

Adcock IngramLimited.Reg.No.1949/034385/06.PrivateBagX69,Bryanston,2021,SouthAfrica. CustomerCare:0860ADCOCK/232625.www.adcock.com.2022021110184020.February2022.C-APROM/ZA/MEZ/0003. Mezavant® (enteric coated,prolonged-release tablet.)Each tablet containsmesalazine1200mg.Reg.No.45/11/0463.TAKEDA (Pty)Ltd.Reg.No.:1982/011215/07.BuildingA,MonteCircle,64MontecasinoBoulevard,Fourways,2191,SouthAfrica.Tel:+27 (0)115143000.Fax:+27 (0)115143001. MarketedbyAdcock IngramHealthcare (Pty)Ltd.Reg.No.:2007/019928/07.PrivateBagX69,Bryanston,2021,SouthAfrica.CustomerCare:0860ADCOCK/232625.www.adcock.com.For fullprescribing information refer to theprofessional informationapprovedby themedicines regulatoryauthority. Mezavant ® is a valuable option in the management of patients with mild to moderate ulcerative colitis 3 Prolonged release mesalazine for patients with mild-to-moderate ulcerative colitis 1,2 2 Hydrophilic matrix Expands on exposure to intestinal fluid and forms a viscous gel – slowing the release of 5-ASA in the colonic lumen 2 Breaks down at pH 7.0 or above (pH usually encountered in the terminal ileum) 2 Gastro-resistant coating Artistic impression - Adapted from Tenjarla S, et al. 2007 2 Gel mass breaks away from the core, exposing 5-ASA to the colon. 2 5-ASA is distributed throughout the colon 2,4 Prolonged drug release Lipophilic matrix Slows penetration of aqueous fluids into the tablet core – reducing the rate of dissolution 2 Suggested mechanism of 5-ASA release* MMX ® TECHNOLOGY FOR PROLONGED DRUG RELEASE 1,2,4,5 DELIVERS MESALAZINE 5-AMINOSALICYLATE (5-ASA) THROUGHOUT THE COLON 1,2,4,5,6 TheapprovedMezavantprofessional information shouldbe consultedbeforeprescribing. 5-ASA:5-acetyl salicylicacid References: 1. Mezavant approved professional information, August 2013. 2. Tenjarla S, RomasantaV, Zeijdner E,Villa R, Moro L. Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system. Advances in Therapy 2007;24(4):826-840. 3. YangLPH,McCormackPL.MMX®Mesalazine:A reviewof itsuse in themanagementofmild tomoderateulcerative colitis. Drugs 2011;71(2):221-235. 4. BrunnerM,AssandriR,KletterK,TschurlovitsM,CorradoMe,VillaR, etal. Gastrointestinal transitand5-ASA release fromanewmesalazineextended- release formulation. Aliment PharmacolTher. 2003;17:395–402. 5. Tenjarla S, Abinusawa A. In-vitro characterization of 5-aminosalicylic acid release from MMX mesalamine tablets and determination of tablet coating thickness. AdvTher 2011;28(1):62-72. 6. Prakash A, Markham A. Oral delayed-release mesalazine:a reviewof itsuse inulcerative colitisandCrohn’sdisease. Drugs. 1999;57(3):383-408. *The release kinetics of 5-ASA from an MMX mesalamine tablet were assessed with the use of a dynamic in vitro gastrointestinal tract system (TNO GastroIntestinal Model) that simulates physiologic conditions in the adult human gastrointestinal tract under standardized fed and fasted conditions. 2